Table 1.
Clinical, radiological, and pathological features of the patients included in the study.
| Variable | Mean (SD) Count (%) |
|
|---|---|---|
| Age | 61.18 (SD = 11.45) | |
| Gender (female:male) | 41:58 | |
| Karnofsky Performance Status (KPS) ≥ 70 | 91 (91.9%) | |
| Neurological deficit | 74 (74.7%) | |
| Epileptic seizures | 16 (16.2%) | |
| Headache | 23 (23.2%) | |
| Brain hemisphere | Left | 57 (57.6%) |
| Right | 40 (40.4% | |
| Bilateral | 2 (2.0%) | |
| Contrast-enhancement type | Ring | 50 (51.0%) |
| Heterogeneous | 47 (48.0%) | |
| No enhancement | 1 (1.0%) | |
| >2 lobes affected | 27 (27.3%) | |
| Subventricular zone involvement | 74 (74.7%) | |
| Corpus callosum involvement | 39 (39.4%) | |
| Internal capsule < 1 cm | 41 (41.4%) | |
| Contrast-enhancement volume (cc) | 21.77 (SD = 15.22) | |
| Edema volumen (cc) | 55.32 (SD = 34.78) | |
| Necrosis volumen (cc) | 9.39 (SD = 9.92) | |
| Necrosis–tumor enhancement ratio (NTR) | 0.41 (SD = 0.41) | |
| ASA | 1–2 | 76 (76.8%) |
| 3–4 | 23 (23.2%) | |
| Risk of serious complication (%) | 7.22 (SD = 3.44) | |
| Risk of any complication (%) | 8.64 (SD = 3.41) | |
| Surgical intention | Biopsy | 31 (31.3%) |
| Complete | 68 (68.7%) | |
| IDH mutation | 1 (1.0%) | |
| Ki-67 > 20% | 47 (52.2%) | |
| MGMT methylation | 57 (58.2%) | |